Pancreatic Cancer Trial, Recruiting NCT05191940 Sponsor: EBG MedAustron GmbH Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT05191940
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with pancreatic cancer, confirmed through a tissue or cell sample — or, in some cases, through scan findings combined with a raised CA 19-9 blood marker (confirm with trial site)
  • People whose cancer cannot be fully removed by surgery, either because the tumour is too close to or wrapped around major blood vessels, or because it has spread to nearby lymph nodes
  • People who were originally considered for surgery but whose cancer grew or spread during pre-surgery chemotherapy, making surgery no longer an option
  • People who are not able to have further pre-surgery chemotherapy — for example, because their health does not allow it, because the cancer stopped responding to it, or because chemotherapy was completed but surgery is still not possible
  • People who have no signs of cancer that has spread to distant parts of the body
  • People aged 18 or older
  • People who score 70 or above on a standard health and activity scale called the Karnofsky index, which measures how well a person is able to carry out daily activities (confirm with trial site)
  • People whose cancer has not grown into the stomach or the first part of the small intestine (duodenum)
  • People who are aware of their diagnosis and are able to give written consent to participate
  • Women of childbearing potential who are using adequate contraception and are not breastfeeding
  • People who have signed a consent form before joining the trial

Who may not be able to join:

  • People whose pancreatic tumour is a type that does not originate from the exocrine part of the pancreas (confirm with trial site)
  • People with serious medical or mental health conditions that would make radiotherapy unsafe
  • People whose cancer has already spread to distant parts of the body
  • People who are pregnant, or who are not willing to use adequate contraception
  • People who are currently breastfeeding and are not willing to stop
  • Men who could father a child and are not willing to use effective contraception
  • People who have metal implants or other conditions that would make it impossible to plan or deliver radiotherapy safely, or who have an active infection in the treatment area (confirm with trial site)
  • People who have previously had radiotherapy to the abdomen
  • People with severely reduced liver or kidney function, as assessed by the treating medical team
  • People who do not wish to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Piero Fossati, M.D., EBG MedAustron GmbH

Phone: +43 664 80878

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
EBG MedAustron GmbH
Registry
ClinicalTrials.gov
Start date
16 May 2022
Est. completion
1 December 2028

Where this trial is recruiting

🇦🇹 Austria

Primary endpoints

Locoregional tumor control

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov